Rhinovirus Infections Drug Global Market Report 2026
상품코드:1957753
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
라이노바이러스 감염증 치료제 시장 규모는 최근 현저한 성장을 이루고 있습니다. 2025년 13억 6,000만 달러에서 2026년에는 14억 8,000만 달러에 이르고, CAGR 8.8%로 성장할 전망입니다. 지난 몇 년간의 성장 요인으로는 높은 감기 발병률, 제한된 항바이러스 치료 옵션, 광범위한 일반의약품 사용, 계절적 감염 패턴, 빠른 증상 완화를 원하는 소비자 수요 등을 꼽을 수 있습니다.
라이노바이러스 감염증 치료제 시장 규모는 향후 몇 년간 강력한 성장이 전망됩니다. 2030년에는 20억 5,000만 달러에 이르고, CAGR은 8.6%를 나타낼 전망입니다. 예측 기간의 성장 요인으로는 항바이러스 연구의 발전, 바이러스 표적화 기술 향상, 호흡기 감염에 대한 인식 제고, 소아용 의약품 개발, 비강 투여 기술 혁신 등을 꼽을 수 있습니다. 예측 기간의 주요 동향으로는 항바이러스 감기 치료제에 대한 조사 증가, 증상 완화 요법에 대한 관심 증가, 비강 점적 제제 확대, 면역 조절제에 대한 관심 증가, 예방적 호흡기 치료로의 전환 등을 들 수 있습니다.
호흡기 질환의 유병률 증가는 라이노바이러스 감염증 치료제 시장의 확대를 촉진할 것으로 예측됩니다. 호흡기 질환이란 천식, 만성폐쇄성폐질환(COPD), 폐렴 등 폐와 기도에 영향을 미쳐 호흡곤란을 유발하는 질환을 말합니다. 이러한 급격한 증가는 주로 대기오염과 직업적 위험에 대한 노출 증가로 인해 취약 계층의 천식, COPD, 폐렴 발병률 증가로 이어지고 있습니다. 라이노바이러스 감염증 치료제는 바이러스 복제를 억제하고 염증을 억제하며 증상을 완화하여 호흡 기능을 개선함으로써 이들 질환의 치료에 도움을 줍니다. 예를 들어, 영국 정부 기관인 건강 개선 및 격차 대책국이 2025년 6월 발표한 보고서에 따르면, 영국에서는 2024년까지 1년간 85만 4,922건의 호흡기 질환으로 인한 응급 입원이 발생했으며, 이는 인구 10만 명당 1,428건으로 전년 대비 7% 증가한 수치입니다. 이처럼 호흡기 질환의 발생률 증가가 라이노바이러스 감염증 치료제 시장의 확대를 견인하고 있습니다.
라이노바이러스 감염증 치료제 시장의 주요 기업들은 치료 효과 향상, 증상 완화, 환자 회복을 촉진하기 위해 항바이러스제 등 혁신적인 제품 개발에 주력하고 있습니다. 항바이러스제는 체내 바이러스 복제를 억제하여 바이러스 감염과 싸우는 역할을 합니다. 이 약제들은 독감, HIV, 간염, 라이노바이러스 등의 질병에 대응합니다. 특정 항바이러스제는 바이러스가 숙주 세포에 침입하는 것을 막고, 다른 약제는 바이러스의 복제와 조립을 방해합니다. 예를 들어, 2025년 3월 미국 바이오테크 기업 알테사 바이오사이언스는 COPD 환자의 라이노바이러스 감염증을 치료하기 위한 신약 개발 신청(IND)에 대해 미국 식품의약국(FDA)의 승인을 획득했습니다. 바펜다빌은 경구용 광범위 항바이러스제로 라이노바이러스가 인간 세포에 침입하여 복제하는 것을 억제합니다. 라이노바이러스 및 기타 호흡기 엔테로바이러스의 97%에서 효과가 확인되었습니다. 알테사 바이오사이언스는 바펜다빌의 개발, 제조, 판매에 대한 전 세계 독점적 권리를 보유하고 있습니다. 이 약은 COPD, 천식 등의 위험군을 대상으로 집중적인 치료를 목표로 하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 공급망 분석
제4장 세계 시장 동향과 전략
제5장 최종 이용 산업 시장 분석
제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오
제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석
제8장 TAM(Total Addressable Market) 규모
제9장 시장 세분화
제10장 지역별/국가별 분석
제11장 아시아태평양 시장
제12장 중국 시장
제13장 인도 시장
제14장 일본 시장
제15장 호주 시장
제16장 인도네시아 시장
제17장 한국 시장
제18장 대만 시장
제19장 동남아시아 시장
제20장 서유럽 시장
제21장 영국 시장
제22장 독일 시장
제23장 프랑스 시장
제24장 이탈리아 시장
제25장 스페인 시장
제26장 동유럽 시장
제27장 러시아 시장
제28장 북미 시장
제29장 미국 시장
제30장 캐나다 시장
제31장 남미 시장
제32장 브라질 시장
제33장 중동 시장
제34장 아프리카 시장
제35장 시장 규제 상황과 투자환경
제36장 경쟁 구도와 기업 개요
제37장 기타 주요 기업 및 혁신 기업
제38장 세계 시장 경쟁 벤치마킹과 대시보드
제39장 주요 인수합병(M&A)
제40장 시장 잠재력이 높은 국가, 부문, 전략
제41장 부록
LSH
영문 목차
영문목차
A drug targeting rhinovirus infections is a medication formulated to prevent, treat, or control infections from rhinoviruses, the leading culprits behind the common cold. These agents function by halting viral replication, preventing viral access to host cells, or adjusting the immune response to lessen symptom intensity and shorten the infection period.
The primary products for rhinovirus infection encompass antivirals, immunomodulators, vaccines, nasal sprays, and symptomatic therapies. Antiviral medications work by targeting the virus itself to lessen infection severity and shorten its duration, fueling market expansion via innovations in pharmaceuticals. These treatments serve diverse patient populations, from infants and children to adults and seniors, delivered via routes like oral, intranasal, or injectable methods. They address conditions including the common cold, asthma flares, COPD exacerbations, and related issues. Available through distribution channels such as hospital pharmacies, retail pharmacies, online pharmacies, and specialty pharmacies.
Tariffs have affected the rhinovirus infections drug market by increasing the cost of imported antiviral APIs, nasal spray components, and immune-modulating excipients. These impacts have been most pronounced in antiviral and nasal spray drug segments, particularly in north america and europe where formulation components are globally sourced. Asia-pacific manufacturers have faced packaging material cost pressures. However, tariffs have encouraged local formulation manufacturing and OTC drug production, improving market accessibility.
The rhinovirus infections drug market research report is one of a series of new reports from The Business Research Company that provides rhinovirus infections drug market statistics, including rhinovirus infections drug industry global market size, regional shares, competitors with a rhinovirus infections drug market share, detailed rhinovirus infections drug market segments, market trends and opportunities, and any further data you may need to thrive in the rhinovirus infections drug industry. This rhinovirus infections drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The rhinovirus infections drug market size has grown strongly in recent years. It will grow from $1.36 billion in 2025 to $1.48 billion in 2026 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to high prevalence of common cold, limited antiviral options, widespread OTC drug usage, seasonal infection patterns, consumer demand for fast relief.
The rhinovirus infections drug market size is expected to see strong growth in the next few years. It will grow to $2.05 billion in 2030 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to advances in antiviral research, improved viral targeting technologies, rising respiratory infection awareness, pediatric drug development, innovation in nasal delivery. Major trends in the forecast period include rising research into antiviral cold treatments, growing focus on symptom reduction therapies, expansion of nasal spray formulations, increased interest in immune-modulating drugs, shift toward preventive respiratory care.
The rising prevalence of respiratory disorders is anticipated to boost the rhinovirus infections drug market. Respiratory disorders are medical conditions impacting the lungs and airways, causing breathing difficulties, including asthma, chronic obstructive pulmonary disease (COPD), and pneumonia. This surge stems mainly from growing air pollution and occupational hazard exposure, resulting in higher rates of asthma, COPD, and pneumonia among vulnerable groups. Rhinovirus infection drugs aid these disorders by inhibiting viral replication, curbing inflammation, and easing symptoms to enhance respiratory performance. For instance, in June 2025, the Office for Health Improvement & Disparities-a UK government agency-reported that England had 854,922 emergency respiratory hospital admissions in the year ending 2024, equating to 1,428 per 100,000 people, a 7% increase from the prior year. Thus, the growing incidence of respiratory disorders fuels expansion in the rhinovirus infections drug market.
Major companies in the rhinovirus infections drug market are prioritizing the development of innovative products, like antiviral drugs, to improve treatment effectiveness, lessen symptom intensity, and speed up patient recovery. Antiviral drugs combat viral infections by blocking viral replication inside the body. These medications address conditions such as influenza, HIV, hepatitis, and rhinovirus. Certain antivirals stop viruses from entering host cells, whereas others hinder viral replication or assembly. For example, in March 2025, Altesa BioSciences Inc., a biotechnology firm based in the US, obtained U.S. Food and Drug Administration (FDA) clearance for its Investigational New Drug (IND) application for vapendavir, aimed at treating rhinovirus infections in individuals with COPD. Vapendavir is an oral broad-spectrum antiviral that blocks rhinovirus from entering and replicating in human cells. It has shown efficacy against 97% of rhinoviruses and other respiratory enteroviruses. Altesa BioSciences possesses exclusive worldwide rights to develop, produce, and market vapendavir. The drug seeks to deliver focused therapy for at-risk groups, such as those with COPD and asthma.
In May 2025, Altesa BioSciences, a US-based biopharmaceutical company offering the oral antiviral drug vapendavir for rhinovirus infections, partnered with VirTus Respiratory Research Ltd. Through this partnership, Altesa seeks to produce key proof-of-concept data on its lead antiviral candidate, vapendavir, to advance into large-scale, late-stage clinical trials for treating virus-induced respiratory exacerbations. VirTus Respiratory Research Ltd. is a U.K.-based contract research organization focused on respiratory disease models and clinical testing.
Major companies operating in the rhinovirus infections drug market are Pfizer Inc., Teva Pharmaceutical Industries Ltd., Cocrystal Pharma Inc., Biota Pharmaceuticals Inc., Romark Laboratories L.C., Altamira Therapeutics Ltd., Pneumagen Ltd., AIM ImmunoTech Inc., hVIVO Services Limited, Maxwell Biosciences Inc., Altesa BioSciences Inc., Via Nova Therapeutics Inc., MetP Pharma AG, Ntvirin Pharma, GlaxoSmithKline plc, Johnson & Johnson, Sanofi S.A., Bayer AG, Cipla Limited, Reckitt Benckiser Group plc
North America was the largest region in the rhinovirus infection drug market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rhinovirus infections drug market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the rhinovirus infections drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The rhinovirus infections drug market consists of sales of decongestants, antihistamines, and pain relievers and fever reducers. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Rhinovirus Infections Drug Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses rhinovirus infections drug market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for rhinovirus infections drug ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The rhinovirus infections drug market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.
4.2.1 Rising Research Into Antiviral Cold Treatments
4.2.2 Growing Focus On Symptom Reduction Therapies
4.2.3 Expansion Of Nasal Spray Formulations
4.2.4 Increased Interest In Immune-Modulating Drugs
4.2.5 Shift Toward Preventive Respiratory Care
5. Rhinovirus Infections Drug Market Analysis Of End Use Industries
5.1 Hospitals
5.2 Primary Care Clinics
5.3 Retail Pharmacies
5.4 Pediatric Clinics
5.5 Homecare Settings
6. Rhinovirus Infections Drug Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market
7. Global Rhinovirus Infections Drug Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis
7.1. Global Rhinovirus Infections Drug PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global Rhinovirus Infections Drug Market Size, Comparisons And Growth Rate Analysis
7.3. Global Rhinovirus Infections Drug Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global Rhinovirus Infections Drug Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)
8. Global Rhinovirus Infections Drug Total Addressable Market (TAM) Analysis for the Market
8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis
9. Rhinovirus Infections Drug Market Segmentation
9.1. Global Rhinovirus Infections Drug Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
9.6. Global Rhinovirus Infections Drug Market, Sub-Segmentation Of Antivirals, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Pleconaril, Vapendavir, Rupintrivir, Other Antivirals
9.7. Global Rhinovirus Infections Drug Market, Sub-Segmentation Of Immunomodulators, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Interferons, Toll-Like Receptor Agonists, Other Immunomodulators
9.8. Global Rhinovirus Infections Drug Market, Sub-Segmentation Of Vaccines, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Live Attenuated Vaccines, Inactivated Vaccines, Recombinant Vaccines
9.9. Global Rhinovirus Infections Drug Market, Sub-Segmentation Of Nasal Sprays, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
9.10. Global Rhinovirus Infections Drug Market, Sub-Segmentation Of Symptomatic Treatments, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
10. Rhinovirus Infections Drug Market Regional And Country Analysis
10.1. Global Rhinovirus Infections Drug Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
10.2. Global Rhinovirus Infections Drug Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
11. Asia-Pacific Rhinovirus Infections Drug Market
11.1. Asia-Pacific Rhinovirus Infections Drug Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Rhinovirus Infections Drug Market, Segmentation By Product, Segmentation By Patient Age Group, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
12. China Rhinovirus Infections Drug Market
12.1. China Rhinovirus Infections Drug Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
12.2. China Rhinovirus Infections Drug Market, Segmentation By Product, Segmentation By Patient Age Group, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
13. India Rhinovirus Infections Drug Market
13.1. India Rhinovirus Infections Drug Market, Segmentation By Product, Segmentation By Patient Age Group, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
14. Japan Rhinovirus Infections Drug Market
14.1. Japan Rhinovirus Infections Drug Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan Rhinovirus Infections Drug Market, Segmentation By Product, Segmentation By Patient Age Group, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
15. Australia Rhinovirus Infections Drug Market
15.1. Australia Rhinovirus Infections Drug Market, Segmentation By Product, Segmentation By Patient Age Group, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
16. Indonesia Rhinovirus Infections Drug Market
16.1. Indonesia Rhinovirus Infections Drug Market, Segmentation By Product, Segmentation By Patient Age Group, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
17. South Korea Rhinovirus Infections Drug Market
17.1. South Korea Rhinovirus Infections Drug Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. South Korea Rhinovirus Infections Drug Market, Segmentation By Product, Segmentation By Patient Age Group, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
18. Taiwan Rhinovirus Infections Drug Market
18.1. Taiwan Rhinovirus Infections Drug Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
18.2. Taiwan Rhinovirus Infections Drug Market, Segmentation By Product, Segmentation By Patient Age Group, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
19. South East Asia Rhinovirus Infections Drug Market
19.1. South East Asia Rhinovirus Infections Drug Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
19.2. South East Asia Rhinovirus Infections Drug Market, Segmentation By Product, Segmentation By Patient Age Group, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
20. Western Europe Rhinovirus Infections Drug Market
20.1. Western Europe Rhinovirus Infections Drug Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
20.2. Western Europe Rhinovirus Infections Drug Market, Segmentation By Product, Segmentation By Patient Age Group, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
21. UK Rhinovirus Infections Drug Market
21.1. UK Rhinovirus Infections Drug Market, Segmentation By Product, Segmentation By Patient Age Group, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
22. Germany Rhinovirus Infections Drug Market
22.1. Germany Rhinovirus Infections Drug Market, Segmentation By Product, Segmentation By Patient Age Group, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
23. France Rhinovirus Infections Drug Market
23.1. France Rhinovirus Infections Drug Market, Segmentation By Product, Segmentation By Patient Age Group, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
24. Italy Rhinovirus Infections Drug Market
24.1. Italy Rhinovirus Infections Drug Market, Segmentation By Product, Segmentation By Patient Age Group, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
25. Spain Rhinovirus Infections Drug Market
25.1. Spain Rhinovirus Infections Drug Market, Segmentation By Product, Segmentation By Patient Age Group, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
26. Eastern Europe Rhinovirus Infections Drug Market
26.1. Eastern Europe Rhinovirus Infections Drug Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Eastern Europe Rhinovirus Infections Drug Market, Segmentation By Product, Segmentation By Patient Age Group, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
27. Russia Rhinovirus Infections Drug Market
27.1. Russia Rhinovirus Infections Drug Market, Segmentation By Product, Segmentation By Patient Age Group, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
28. North America Rhinovirus Infections Drug Market
28.1. North America Rhinovirus Infections Drug Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
28.2. North America Rhinovirus Infections Drug Market, Segmentation By Product, Segmentation By Patient Age Group, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
29. USA Rhinovirus Infections Drug Market
29.1. USA Rhinovirus Infections Drug Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
29.2. USA Rhinovirus Infections Drug Market, Segmentation By Product, Segmentation By Patient Age Group, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
30. Canada Rhinovirus Infections Drug Market
30.1. Canada Rhinovirus Infections Drug Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
30.2. Canada Rhinovirus Infections Drug Market, Segmentation By Product, Segmentation By Patient Age Group, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
31. South America Rhinovirus Infections Drug Market
31.1. South America Rhinovirus Infections Drug Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
31.2. South America Rhinovirus Infections Drug Market, Segmentation By Product, Segmentation By Patient Age Group, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
32. Brazil Rhinovirus Infections Drug Market
32.1. Brazil Rhinovirus Infections Drug Market, Segmentation By Product, Segmentation By Patient Age Group, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
33. Middle East Rhinovirus Infections Drug Market
33.1. Middle East Rhinovirus Infections Drug Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
33.2. Middle East Rhinovirus Infections Drug Market, Segmentation By Product, Segmentation By Patient Age Group, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
34. Africa Rhinovirus Infections Drug Market
34.1. Africa Rhinovirus Infections Drug Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
34.2. Africa Rhinovirus Infections Drug Market, Segmentation By Product, Segmentation By Patient Age Group, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
35. Rhinovirus Infections Drug Market Regulatory and Investment Landscape
36. Rhinovirus Infections Drug Market Competitive Landscape And Company Profiles
36.1. Rhinovirus Infections Drug Market Competitive Landscape And Market Share 2024
36.1.1. Top 10 Companies (Ranked by revenue/share)
36.2. Rhinovirus Infections Drug Market - Company Scoring Matrix
36.2.1. Market Revenues
36.2.2. Product Innovation Score
36.2.3. Brand Recognition
36.3. Rhinovirus Infections Drug Market Company Profiles
36.3.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
36.3.2. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
36.3.3. Cocrystal Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis
36.3.4. Biota Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
36.3.5. Romark Laboratories L.C. Overview, Products and Services, Strategy and Financial Analysis
37. Rhinovirus Infections Drug Market Other Major And Innovative Companies
